Table 3 Univariate analyses of potential prognostic factors for progression-free survival (PFS)
Factors | PFS at 1 year (%) | PFS at 2 years (%) | PFS at 5 years (%) | p-value |
|---|---|---|---|---|
Age | ||||
65–74 years | 70 | 43 | 23 | |
75–84 years | 79 | 60 | 23 | |
≥ 85 years | 63 | 47 | 31 | 0.60 |
Gender | ||||
Female | 71 | 50 | 32 | |
Male | 72 | 49 | 20 | 0.30 |
ECOG score | ||||
0–1 | 70 | 50 | 24 | |
2–3 | 85 | 46 | 23 | 0.60 |
Charlson Comorbidity Index | ||||
≤ 5 | 59 | 39 | 25 | |
> 5 | 50 | 29 | 6 | 0.05 |
Clinical tumor classification (cT) | ||||
1 | 50 | - | - | |
2 | 92 | 50 | 17 | |
3 | 69 | 53 | 30 | |
4 | 70 | 30 | 10 | 0.70 |
Clinical lymph node classification (cN) | ||||
Nodal negative (N0) | 82 | 61 | 19 | |
Nodal positive (N +) | 70 | 46 | 24 | 0.50 |
Tumor stage (AJCC) | ||||
1–3 | 71 | 51 | 25 | |
4a | 75 | 43 | 17 | 0.50 |
Localization of the primary tumor | ||||
15–32 cm distance from the incisors | 77 | 61 | 45 | |
33 cm distance from the incisors until gastroesophageal junction | 71 | 45 | 18 | 0.05 |
Administration of full-dose RT | ||||
Yes | 67 | 33 | - | |
No | 73 | 50 | 24 | 0.40 |
Cumulative dose of RT (EQD2) | ||||
≤ 50 Gy | 75 | 46 | 29 | |
> 50 Gy | 69 | 53 | 19 | 0.70 |
Administration of non-modified, full-dose chemotherapy | ||||
Yes | 77 | 60 | 38 | |
No | 70 | 43 | 17 | 0.79 |
Treatment concept | ||||
Neoadjuvant CRT followed by surgical resection | 86 | 60 | 43 | |
Definitive RT / CRT | 64 | 43 | 15 | 0.01 |